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OBJECTIVES: Although liver biopsy is the gold standard for determining the degree of liver fibrosis, issues
regarding its invasiveness and the small amount of liver tissue evaluated can limit its applicability and
interpretation in clinical practice. Non-invasive evaluation methods for liver fibrosis can address some of these
limitations. The aim of this study was to evaluate the accuracy of transient elastography-FibroScans, acoustic
radiation force impulse (ARFI), enhanced liver fibrosis (ELF), the aspartate aminotransferase-to-platelet ratio
index (APRI), and the FIB-4 index compared with liver biopsy in hepatitis C.
METHODS: We evaluated chronic hepatitis C patients who were followed at the Division of Clinical Gastroenter-
ology and Hepatology, Hospital das Clı´nicas, Department of Gastroenterology of University of Sa˜o Paulo School of
Medicine, Sa˜o Paulo, Brazil, and who underwent liver biopsy. The accuracy of each method was determined by a
receiver operating characteristic (ROC) curve analysis, and fibrosis was classified as significant fibrosis (XF2),
advanced fibrosis (XF3), or cirrhosis (F4). The Obuchowski method was also used to determine the diagnostic
accuracy of each method at the various stages of fibrosis. In total, 107 FibroScans, 51 ARFI, 68 ELF, 106 APRI, and
106 FIB-4 analyses were performed.
RESULTS: A total of 107 patients were included in the study. The areas under the ROC curve (AUROCs) according
to fibrosis degree were as follows: significant fibrosis (XF2): FibroScans: 0.83, FIB-4: 0.76, ELF: 0.70, APRI: 0.69,
and ARFI: 0.67; advanced fibrosis (XF3): FibroScans: 0.85, ELF: 0.82, FIB-4: 0.77, ARFI: 0.74, and APRI: 0.71; and
cirrhosis (F4): APRI: 1, FIB-4: 1, FibroScans: 0.99, ARFI: 0.96, and ELF: 0.94. The accuracies of transient elasto-
graphy, ARFI, ELF, APRI and FIB-4 determined by the Obuchowski method were F0-F1: 0.81, 0.78, 0.44, 0.72 and
0.67, respectively; F1-F2: 0.73, 0.53, 0.62, 0.60, and 0.68, respectively; F2-F3: 0.70, 0.64, 0.77, 0.60, and 0.67,
respectively; and F3-F4: 0.98, 0.96, 0.82, 1, and 1, respectively.
CONCLUSION: Transient elastography remained the most effective method for evaluating all degrees of fibrosis.
The accuracy of all methodologies was best at F4.
KEYWORDS: Hepatitis C Chronic; Liver Cirrhosis; Elastography; Biomarkers/Blood; Disease Progression;
Data Accuracy.
Ragazzo TG, Paranagua-Vezozzo D, Lima FR, Mazo DF, Pessoa MG, Oliveira CP, et al. Accuracy of transient elastography-FibroScans, acoustic
radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients
with chronic hepatitis C. Clinics. 2017;72(9):516-525
Received for publication on December 15, 2016; First review completed on February 9, 2017; Accepted for publication on March 15, 2017
*Corresponding author. E-mail: taisagr@usp.br
’ INTRODUCTION
There are approximately 130 to 150 million carriers of the
hepatitis C virus (HCV) worldwide. Approximately 55-85%
of patients with HCV develop the chronic form of the disease,
and approximately 15-30% of these patients are at risk of
developing cirrhosis within 20 years of diagnosis. Approxi-
mately 300,000-500,000 people die each year as a result ofDOI: 10.6061/clinics/2017(09)01
Copyright & 2017 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
516
CLINICAL SCIENCE
complications arising from HCV (1). In Brazil, hepatocellular
carcinoma (HCC) is one of the most frequent complications
of cirrhosis caused by HCV (2,3).
Liver biopsy is still considered the gold standard for liver
tissue evaluation, allowing the ascertainment not only of
the degree of fibrosis but also of other important parame-
ters, such as inflammation, necrosis, steatosis, and the pre-
sence of hepatic iron in the sample obtained (4). However,
liver biopsy is an invasive procedure that carries risks,
sometimes causing pain, hemorrhage, and even death,
among other complications (5). Issues regarding the quality
of the liver samples and interpretation of the results can
also occur. The quality of a liver biopsy is generally related
to the length and number of portal spaces evaluated (6,7).
The results of the pathological anatomy can vary accord-
ing to the subjective interpretation of the individual patho-
logist (8).
Due to these limitations, non-invasive methods of liver
fibrosis evaluation have been studied intensely and have
improved over recent decades. These methods can be divi-
ded into two categories, namely, indirect markers, which can
be assessed by routine clinical exams (e.g., aminotransferases
and platelet count) (9), and direct markers, which include
serum levels of substances involved in the molecular patho-
genesis of fibrosis, such as matrix metalloproteinases, hyalu-
ronic acid, and cytokines [tumor necrosis factor a (TNF-a)
and transforming growth factor b (TGF-b)] (10).
Elastography methods use an existing modality, such as
ultrasound (US), to observe the internal tissue deformations
that occur in response to an applied force and convert the
resulting information to a suitable form for display. A wide
variety of approaches have evolved, both for applying
the force and for measuring and displaying the tissue’s
response after applying a force that is either dynamic
(e.g., by thumping or vibrating) or that varies so slowly that
it is considered "quasi-static" (e.g., by probe palpation). The
deformation may be represented in an elasticity image
(elastogram) or as a local measurement of tissue displace-
ment that may be detected and displayed directly [Acoustic
Radiation Force Impulse (ARFI) imaging]. Another form of
representation is through the regional values of their speed
(without making images) using methods referred to herein as
transient elastography (TE) (11).
The aim of this study was to evaluate the accuracy of
TE-FibroScans, ARFI imaging, enhanced liver fibrosis (ELF),
the aspartate aminotransferase-to-platelet ratio index (APRI),
and FIB-4 compared with liver biopsy in chronic hepatitis C
patients.
’ PATIENTS AND METHODS
We performed a prospective study evaluating treatment-
naive patients chronically infected with HCV, who were on
the waiting list for liver biopsy at the outpatient clinic of the
Division of Clinical Gastroenterology and Hepatology, Hospi-
tal das Clínicas, Department of Gastroenterology of Univer-
sity of São Paulo School of Medicine, São Paulo, Brazil
(HC-FMUSP), from August 3, 2012, to May 31, 2014. A total of
107 patients were included, with 107 liver biopsies, 107 TE
exams, 106 APRI and FIB-4 exams, 68 ELF exams and 51 ARFI
exams performed.
The liver biopsies were performed with a 14-G Tru-Cutt
needle (15cm) (Medical Technology, Gainesville, FL, USA).
Liver histology was examined by the same experienced liver
pathologist from the Department of Pathology of HC-FMUSP
to avoid operator bias in the analysis. The selected samples
had a minimum of 5 portal spaces (a mean of 13 portal spaces:
43 biopsies had between 5 and 10 portal spaces and 64 had
between 11 and more than 35 portal spaces) and a mean size
of 15 mm (varying between 7 and 23 mm). The classifica-
tion score used for analysis of the biopsies was the METAVIR
score (12).
The inclusion criteria were as follows: 1. HCV PCR-RNA
positivity for at least 6 months and a clinical or histopatho-
logical diagnosis of treatment- naive HCV; 2. negative
serological test for hepatitis B or HIV co-infection; and
3. representative liver biopsy (minimum of 5 portal spaces,
non-subcapsular fragment) performed 60 days prior to
the exams. The exclusion criteria were as follows: 1. refusal
to provide informed consent; 2. patient under 18 or over
70 years of age; 3. unavailability of liver biopsy (contra-
indication); 4. biopsies performed more than 60 days before
the evaluation; 5. non-representative liver biopsy; 6. clinical
suspicion or image evidence of HCC; 7. ascites; 8. body mass
index (BMI) X30kg/m2 and 9. previous treatment for HCV.
10. unreliable FibroScans results (as described later).
The following examinations were utilized for fibrosis
evaluation: TE-FibroScans, ARFI, ELF, APRI, and FIB-4.
FibroScans was developed by Echosens (Paris, France) in
2003 (13). The equipment consists of a 5-MHz US transducer
coupled to a base with a vibratory axis, and it uses VCTE
technology (elastography technology with velocity-control-
led impulses). The vibration emitted by the transducer is
of medium amplitude (2 mm) and low frequency (50 Hz).
It produces a wave through the liver tissue, which allows
estimation of the elasticity of the hepatic parenchyma
through the equation E=3pV2, where: E=elasticity, p=density
(a constant in tissue), and V=velocity of wave propagation.
The denser the tissue, the faster the wave propagates. The
results of liver elasticity measurements are expressed in
kilopascals (kPa) in an interval of 2.5-75 kPa. The section
analyzed corresponds to a cylinder 1 cm in diameter and
4 cm in length, corresponding to a volume 100-fold larger
than that obtained with liver biopsy (11,13-15). A liver stif-
fness assessment is generally considered reliable when the
following criteria are fulfilled: 10 valid measurements, suc-
cess rate 460%, and ratio of the interquartile range to the
median (IQR/M)p30% (16-18). Patients with invalid/ unre-
liable measurements were excluded from the study. The TE
examinations in this study were performed by the same
experienced and highly trained operator, thus eliminating
the risk of inter-observer bias. All patients fasted for at least
three hours prior to examination because the FibroScans
reading (in kPa) varies immediately following food con-
sumption, altering the result (19). The inclusion criteria of
BMIp30 kg/m2 and skin-liver distance are factors that affect
the choice of transducer used. The M transducer was used for
all TE examinations in this study to avoid potential bias in
interpreting the results in kPa because when both the M, and
XL transducers are used, different results can occur (20-22).
ARFI imaging (Siemens Acuson S2000, Virtual Touchä tis-
sue quantification; Siemens, Erlangen, Germany) is another
tool for evaluating liver stiffness that can be incorporated
into a conventional US machine. Transducers sensitive to the
propagation of acoustic pulses of a frequency of 2.67 Hz
generate shear waves that propagate in the tissue perpendi-
cular to the direction of the acoustic impulse. The shear
waves are then tracked using US based on correlation in a
517
CLINICS 2017;72(9):516-525 Accuracy of transient elastrography
Ragazzo TG et al.
small region of interest (ROI) of 5 mm x 10 mm, which the
operator can easily locate in the field of vision up to a depth
of 8 cm with a convex catheter. This allows the detection of
liver stiffness through the velocity of propagation of the
shear wave, which is linearly correlated with the stiffness of
the liver (11,23,24). The results are expressed in meters per
second (m/s) with an interval scale of 0.5-4.4 m/s and
precision of ±20% related to the interval (25). A result is
considered high quality when 10 valid measurements are
recorded with an IQR/M ratio o30% and a success rate of
X60% (26). The examination is performed at the height of
the medial axillary line and the xiphoid appendage with a
projection of S8.
As a direct method utilizing biomarkers in the blood,
ELF is a serum test that yields a single value, combining
quantitative measures of hyaluronic acid (HA), pro-peptide
amino-terminal of pro-collagen type III (PIIINP), and tissue
inhibitor metalloproteinase 1 (TIMP-1) in human serum in
an algorithm (10,27). The ADVIA Centaurs CP was used
for ELF, following formula was applied to yield results:
2.494+0.846 In (C HA) + 0.735 In (C PIIINP) + 0.391 In
(C TIMP-1).
Regarding the methods using indirect biomarkers, APRI
and FIB-4 were calculated through the following scores:
APRI score= [(AST/ULN) 100]/platelet count 109/L. (28)
(ULN: upper limit of normal)
FIB-4 score= {[age (yr) x AST (U/L)] / [platelet count (109/L)
x ALT (U/L)]} (29)
The study was approved by the Ethics Committee of HC-
FMUSP. Of the 250 patients eligible for the study, 143 were
excluded for various reasons, as described in Figure 1. Among
the patients with liver biopsy, 20 were excluded due to non-
representative liver histology (o5 portal spaces and/or non-
subcapsular fragment), and 5 patients were excluded because
of unreliable FibroScans results (one patient presented with
narrow intercostal space, 3 patients had IQR/M 430%
and one patient had an exam success rateo60%). A total of
107 patients were included, as shown in Figure 1.
Statistical analyses
The R package version 3.2.1(R Core Team, Vienna, Austria)
was used for statistical and graph analyses. The performance
of the non-invasive methods was estimated using ROC
curves (using the package pROC version 1.8) by identifying
the optimal cut-off points of different degrees of liver fibrosis
in terms of sensitivity and specificity. The area under the
ROC curve (AUROC) indicates the accuracy of the studied
methods. The Obuchowski method was used to determine
the accuracy of the non-invasive methods of liver fibrosis
evaluation (30,31)
Comparative analyses of more than two groups were
performed using analysis of variance (ANOVA), the Levene
statistic and the Kruskal-Wallis test. For multiple analyses,
or analyses of two groups with more than two other groups,
the Tukey and non-parametric Tukey tests were used. For
qualitative (categorical) variables, Fisher’s exact test and
the chi-squared test were used. Statistical significance was
defined as po0.05.
’ RESULTS
A total of 107 patients were included. The population’s
gender was 50.4% (n=54) female, with 67.2% (n=72) of white
ethnicity and 31.7% (n=34) of black ethnicity. In terms of
exposure to HCV, 27.2% (n=29) had a history of blood trans-
fusion and 25.2% (n=27) contracted the virus through tattooing.
Genotype 1 was the most common, found in 81.9% of cases.
One of the assessed patients had genotype 1 and genotype 2
co-infection. The degree of fibrosis according to the METAVIR
scale was as follows: F0=7.4% (n=8), F1=40.1% (n=43), F2=28.9%
(n=31), F3=21.5% (n=23), and F4=1.8% (n=2). Table 1 shows
anthropometric and laboratory data according to the degree of
fibrosis, demonstrating the importance of clinical and laboratory
parameters according to liver disease severity.
Figures 2, 3 and 4 and Tables 2, 3 and 4 present ROC
curves and statistical characteristics for significant fibrosis
(XF2), advanced fibrosis (XF3) and cirrhosis (F4), respectively.
Figure 1 - Flowchart of study population enrollment.
HCV= hepatitis C virus, HCC= hepatocellular carcinoma.
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Table 5 shows the accuracy of the non-invasive methods of
liver fibrosis evaluation.
’ DISCUSSION
Several factors can influence the results of non-invasive
methods of liver fibrosis evaluation. Regarding TE, fasti-
ng, operator bias, and anthropometric characteristics can
influence the success and reliability of FibroScans (32,33). TE
examinations were performed taking into account these
variables, as described in the Methods section. Two factors
can influence the results of ARFI. High BMI can cause under-
estimation of fibrosis, and a skin-liver distance 42.5 cm
increases the discrepancy compared with liver biopsy (34,35).
Gender can also be a confounding factor in ARFI. Male
patients typically have higher ARFI values than female
Table 1 - Correlation of anthropometric and laboratory data with fibrosis stage according to METAVIR score (means±standard
deviation).
Degree of Fibrosis
F0(n=8) F1(n=43) F2(n=31) F3 (n=23) F4(n=2)
Age (years) 40.6±9.8 44.8±10.9 49.9±9.9 53.8±8.9 56.5±3.5
BMI 25.5±2.7 24.7±2.8 24.9±3.0 25.6±2.6 23.9±5.5
WC (cm) 94.3±8.1 92.1±6.7 92.1±8.3 94.5±7.8 92±15.5
SLD (cm) 1.6±0.1 1.5±0.2 1.5±0.3 1.6±0.4 1.6±0.7
AST (U/L) 25.8±7 35.9±13.2 46.5±31.3 57.2±39.7 181±15.5
ALT (U/L) 32.1±16.3 47.8±24.4 65.9±67.7 75.0±57.6 136.5±16.2
AP (U/L) 66.7±16.1 66.3±17.9 71.7±22.1 71.2±23.3 227.5±136.4
gGT(U/L) 56.1±69.8 54.4±41.6 142.2±169.3 105.4±95.9 249±16.9
ALB (g/dL) 4.2±0.2 4.4±0.3 4.5±0.2 4.3±0.4 4.05±0.2
INR 1.0±0.1 1.0±0.1 1.0±0.1 1.0±0.1 1.1±0.1
PTL (/mm3) 237x103±36x103 234x103±57x103 214x103±46x103 194x103±66x103 118x103±35x103
BMI=body mass index, WC=waist circumference, SLD=skin-liver distance, AST=aspartate aminotransferase, ALT=alanine aminotransferase, FA=alkaline
phosphatase, gGT=gamma glutamyltransferase, ALB=albumin; INR=international normalized ratio, PTL= platelet count.
Figure 2 - ROC curve for significant fibrosis (XF2).
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patients (23). ELF can be affected by age; the frequencies of
cardiovascular disease and chronic inflammatory diseases
are higher in older populations (36,37).
With significant fibrosis defined as XF2, FibroScans
showed a higher degree of accuracy than the other methods
assessed. An AUROC of 0.836 is considered an extremely
good result (38). ELF also showed good results, with an
AUROC of 0.707. ARFI and APRI both showed sufficiently
satisfactory results, with AUROC values of 0.672 and 0.691,
respectively. In the ROC curve for APRI, it was not possible
to distinguish a cut-off point between F1 and F2; therefore, it
was not possible to separate F1/F2 in the analysis of group
F2F3F4 (XF2). FibroScans and ELF were extremely effective
in identifying advanced fibrosis (XF3), with AUROCs of
0.85 and 0.82, respectively. FIB-4, ARFI, and APRI all yielded
results that were considered good, with AUROCs of 0.77,
0.74, and 0.71, respectively. All of the methods were excellent
in identifying cirrhosis (F4) with AUROCs of 0.94 for ELF,
0.969 for ARFI, 0.995 for FibroScans, 1 for APRI and 1 for
FIB-4.
In this study, FibroScans was consistently accurate in
classifying degrees of fibrosis as XF2, XF3, or F4 with
AUROCs of 0.83, 0.85, and 0.99 respectively, which was
consistent with the findings of Castera et al. (16) (XF2
AUROC 0.83, Se: 67, Sp: 89; XF3 AUROC: 0.90, Se: 73, Sp:
91; and F4 AUROC: 0.95, Se: 87, Sp: 91) and of Ziol et al. (39)
(XF2 AUROC: 0.79, Se: 56, Sp: 91;XF3 AUROC: 0.96, Se: 86,
Sp: 85; F4 AUROC: 0.97, Se: 86, Sp: 96). The specificity
and sensitivity of FibroScans were highest at XF4 (40).
FibroScans has also proven to be an effective method of
assessing fibrosis progression for a variety of other pathol-
ogies, such as hepatic steatosis (41). It is also applicable in the
evaluation of fibrosis progression and complications, such as
portal hypertension (42,43), and in the clinical treatment of
HCV and other chronic liver diseases (44,45).
Gara et al. (46) showed that, despite the high sensitivity
and specificity of FibroScans and ARFI in the diagnosis of
cirrhosis, due to the possibility of false-positives, it is always
necessary to view the results in the context of clinical exams
or an imaging exam. ARFI had AUROCs of 0.67 for XF2
(Se: 64, Sp: 69), 0.74 for XF3 (Se: 57, Sp: 74), and 0.97 for F4
(Se: 100, Sp: 97) in this study. ARFI showed less accuracy
than that found in the literature. In the meta-analysis by
Friedrich-Rust et al. (21), the mean AUROCs for ARFI
were 0.87, 0.91, and 0.93 for XF2, XF3 and F4, respectively.
A meta-analysis by Nierhoff et al. (47) yielded AUROCs of
0.84, 0.89 and 0.91 for XF2, XF3, and F4 respectively,
indicating that FibroScans is a good tool for diagnosing
significant fibrosis, and an excellent tool for diagnosing
advanced fibrosis or cirrhosis. Regarding the findings rela-
ted to ARFI and FibroScans, this study revealed differen-
ces from the meta-analysis of Bota et al. (48), who found
FibroScans and ARFI to be equally accurate in diagnosing
significant fibrosis and cirrhosis. Our study revealed
Figure 3 - ROC curve for advanced fibrosis (XF3).
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FibroScans to be superior to ARFI in diagnosing significant
fibrosis. Perhaps the predominance in this study of fibrosis
at stages F0, F1, and F2 could account for this divergence
from the literature. However, there are studies that found
equivalency between FibroScans and ARFI for diagnosing
advanced fibrosis and cirrhosis but that revealed FibroScans
as the better choice for identifying significant fibrosis (49).
In two comparative analyses (50,51), both ARFI and APRI
demonstrated the ability to evaluate the progression of
advanced fibrosis and cirrhosis in HCV, with ARFI exhibiting
slightly better accuracy (50,51).
For ELF, we found AUROCs of 0.71 for XF2 fibrosis
(Se: 82, Sp: 56), 0.82 forXF3 fibrosis (Se: 83, Sp: 69), and 0.94
for F4 fibrosis (Se: 100, Sp: 100). Despite presenting inferior
accuracy for XF2 fibrosis compared with other studies
(10,52), ELF produced results similar to those of Parkes et al.
(53), with AUROCs of 0.74, 0.84 and 0.90 forXF2,XF3, and
F4 fibrosis, respectively, in a specific HCV population. Fagan
et al. (54) found that a cut-off score for ELF of X9.8 had a
sensitivity of 74.4% and a specificity of 92.4% for advanced
fibrosis. In this study, the cut-off for XF3 fibrosis was 9.4
with Se=83 and Sp=69.
In the present study, APRI had a XF3 AUROC: 0.71 and
an F4 AUROC of 1. This result differ from the original work,
which revealed aXF3 AUROC of 0.88 and an F4 AUROC of
0.94 (24). APRI could not identify the individual stages of
fibrosis, and the fibrosis of some patients remained unclassi-
fied when the initial cut-off was applied. Furthermore, the
appropriate definition of the limits of normal AST remains
uncertain. Each laboratory establishes a different value for
the upper limit of normal (55). APRI and FIB-4 are excellent
for cirrhosis, but care should be taken with regard to the
few patients who have test results close to normal levels.
These patients are at risk for false-negative results; therefore,
the tests should be performed alongside imaging examina-
tions (56).
Among the various comparative studies of non-invasive
methods of liver fibrosis assessment, Crisan et al. (57)
showed good results for the accuracy of APRI, FIB-4, and
FibroScans in diagnosing XF3 fibrosis. Peterson et al. (58)
evaluated APRI and ELF in case of significant fibrosis.
That study differed from the others in that it did not use
the METAVIR classification, but it demonstrated that
one methodology can complement the others in some cases.
Poynard et al. (59) conducted a meta-analysis of a variety of
chronic liver diseases and confirmed the accuracy of FIB-4
and APRI in identifying advanced fibrosis and cirrhosis in
HCV.
The results using the Obuchowski method revealed the
degree of fibrosis, and it was impossible to distinguish
between significant fibrosis, advanced fibrosis, and cirrhosis.
In almost all stages of fibrosis, FibroScans was the most
Figure 4 - ROC curve for cirrhosis (F4).
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accurate method. It was most accurate at the extremes of
F1 and F4, with values of 0.81 and 0.98, respectively, and
demonstrated lower accuracy at intermediate stages. ELF
showed exactly the same accuracy at F4 in this study as the
only other published study that used the Obuchowski
method (60).
A limitation of our study is the small sample size, espe-
cially in patients at the extremes of the classification of
hepatic fibrosis, F0 and F4. This may have had an impact on
the results, as previously discussed.
FibroScans was the most accurate method in diagnosing
significant fibrosis (XF2) and advanced fibrosis (XF3) (with
AUROCs of 0.84 and 0.85 respectively). APRI and FIB-4 were
also very accurate in identifying cirrhosis. The accuracy of all
the methodologies was best at F4, but the TE remained the
most effective method for evaluating all degrees of fibrosis.
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